Lee Jerry C, Fong Lawrence
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Clin Cancer Res. 2022 Sep 1;28(17):3633-3635. doi: 10.1158/1078-0432.CCR-22-1520.
Vopratelimab, an anti-ICOS (inducible costimulator of T cells) agonist, alone and in combination with nivolumab, possesses limited toxicity and modest clinical activity in a large phase I/II trial. This treatment induced ICOS expression of CD4+ T cells, which may enable biomarkers for patient selection. Nevertheless, T-cell agonists as cancer immunotherapies continue to be challenging. See related article by Yap et al., p. 3695.
沃普拉替单抗是一种抗ICOS（T细胞诱导共刺激分子）激动剂，在一项大型I/II期试验中，其单独使用及与纳武单抗联合使用时，毒性有限且临床活性适度。这种治疗诱导了CD4+ T细胞的ICOS表达，这可能有助于筛选患者的生物标志物。然而，T细胞激动剂作为癌症免疫疗法仍然具有挑战性。见Yap等人的相关文章，第3695页。
